{
  "alleleExist":true,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"CTNNB1 (\u03b2-catenin), a transcriptional activator, is recurrently mutated in various cancers including endometrial and hepatocellular cancers.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":true,
  "lastUpdate":"11/16/2020",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "21060032",
        "15064718",
        "17172831",
        "16258095"
      ]
    },
    "description":"The CTNNB1 D32N mutation is located in the N-terminus of the protein. This mutation has been found in brain cancer (PMID: 16258095, 17172831, 21060032). Expression of this mutation in an embryonic kidney cell line demonstrated that it is activating as measured by increased protein activity compared to wildtype (PMID: 15064718).",
    "knownEffect":"Gain-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"D32N",
    "alterationType":null,
    "consequence":"missense_variant",
    "entrezGeneId":1499,
    "hgvs":null,
    "hugoSymbol":"CTNNB1",
    "id":null,
    "proteinEnd":32,
    "proteinStart":32,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":true,
  "variantSummary":"The CTNNB1 D32N mutation is likely oncogenic.",
  "vus":false
}